Luzitin

Luzitin, S.A. is a pharmaceutical company focused on the pursuit of innovative solutions for photodynamic therapy (PDT) and photodiagnosis (PDD). Luzitin is open to different investment modalities, from equity sharing to licensing and/or co-development of its therapeutic solutions. There are three unique opportunities for partnership development of Redaporfin: Redaporfin combined with immune checkpoint inhibitors based on its meaningful in-vivo preclinical immunologic effects to treat melanoma. | Redaporfin to treat biliary tract cancer for which EMA has granted Orphan Drug Designation and for which a pivotal study is planned. This provides a further opportunity for fast track status. Application for Orphan Drug Designation by the FDA is planned for later in 2016. | Redaporfin to treat head and neck cancer in combination with immune checkpoint inhibitors.